Sandip Kapadia Sells 25,000 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) CFO Sandip Kapadia sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total transaction of $1,004,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Harmony Biosciences Price Performance

NASDAQ HRMY traded down $0.65 on Thursday, hitting $38.01. 961,233 shares of the company were exchanged, compared to its average volume of 581,495. Harmony Biosciences Holdings, Inc. has a 1-year low of $28.14 and a 1-year high of $41.61. The firm has a 50 day moving average of $34.66 and a two-hundred day moving average of $35.05. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The company has a market cap of $2.17 billion, a P/E ratio of 18.01, a P/E/G ratio of 0.53 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. During the same period in the prior year, the business earned $0.63 earnings per share. Harmony Biosciences's quarterly revenue was up 16.0% on a year-over-year basis. On average, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Hedge Funds Weigh In On Harmony Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Pacer Advisors Inc. increased its stake in Harmony Biosciences by 18.2% during the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock worth $78,452,000 after purchasing an additional 351,582 shares in the last quarter. KBC Group NV boosted its stake in Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after purchasing an additional 819 shares during the period. Janney Montgomery Scott LLC increased its holdings in Harmony Biosciences by 9.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 17,445 shares of the company's stock worth $600,000 after purchasing an additional 1,550 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Harmony Biosciences by 43.1% in the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the company's stock valued at $774,000 after purchasing an additional 6,774 shares in the last quarter. Finally, ARS Investment Partners LLC bought a new position in shares of Harmony Biosciences during the 4th quarter worth approximately $841,000. 86.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on HRMY shares. Needham & Company LLC reissued a "buy" rating and issued a $52.00 price target on shares of Harmony Biosciences in a research report on Monday, January 13th. Cantor Fitzgerald raised their target price on Harmony Biosciences from $51.00 to $58.00 and gave the company an "overweight" rating in a report on Wednesday, October 30th. Oppenheimer reiterated an "outperform" rating and set a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Mizuho raised their price objective on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an "outperform" rating in a research note on Thursday, October 10th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $75.00 target price on shares of Harmony Biosciences in a research report on Thursday, January 16th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.